Prof Charles Coutant — Top 1% Breast Neoplasms

Prof Charles Coutant is an expert in Oncology at Centre Georges François Leclerc (France). As of October 2026, ScienceLeadR ranks Charles Coutant in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Charles Coutant has authored 342 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 2 of them ongoing. SLR score: 882 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Gynecology - Obstetrics - Plastic And Esthetic Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 18, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026

Source: PubMed

Centre Georges François Leclerc

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 342

Citations

Citations: 7 829 1st author: 16 Last author: 43 Unique author: 2

Main journals

Gynecol Obstet Fertil 17

Best Journals

J Clin Oncol 14

Ann Oncol 9

N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy. PMID 41518683 — breast neoplasms, neoplasms, biopsy, drug therapy, solutions, deep learning, breast, therapeutics, learning, chemotherapy	Eur J Cancer	2026
Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database Study. PMID 41046190 — quality of life, mastectomy, breast neoplasms, neoplasms, signs and symptoms, mammaplasty, breast, body image, mutation	Clin Breast Cancer	2025
Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes. PMID 40993786 — lymph nodes, breast neoplasms, neoplasms, positron emission tomography computed tomography, neoplasm metastasis, lymph, breast, therapeutics	Cancer Imaging	2025
Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study. PMID 40777863 — pregnancy, time-to-pregnancy, fertility, breast neoplasms, neoplasms, cohort studies, breast, research	EClinicalMedicine	2025
Comparison of post-operative complications after immediate breast reconstruction by muscle-sparing latissimus dorsi flap versus total latissimus dorsi flap. PMID 40527719 — muscles, neoplasms, mammaplasty, breast, multivariate analysis	Bull Cancer	2025

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Director: 1

By phase:

N/A 8

Phase 2 1

By status:

Recruiting 5

Completed 2

Active not recruiting 1

Not yet recruiting 1

By type:

Interventional 8

Observational 1

By Monocentric/Multicentric:

monocentric 5

multicentric2to4 1

multicentric5to9 0

multicentricup10 3

Main Topics

Skin and Connective Tissue Diseases 5

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Omission of Surgery for Triple negative Breast Cancer in Complete Response After Neoadjuvant Chemo immunotherapy NCT07357948 — triple negative breast neoplasms, breast neoplasms, neoplasms, immunotherapy, breast, therapeutics	N/A	Not yet recruiting	2026
Health Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer NCT04176809 — quality of life, breast neoplasms, neoplasms, tablets, diet, solutions, fatigue, breast, therapeutics, software	N/A	Recruiting	2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice

Charles Coutant